Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients : Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients
Low-risk patients with viral pneumonia do not benefit from and may be harmed by antibiotic therapy. In this study, an alert will appear in the electronic health record of patients undergoing molecular diagnostic testing for respiratory symptoms that provides options for diagnostic testing based on pre-test probability of bacterial infection. Patients with test results suggesting possible viral infection will be randomized to either usual care or to receive test results along with structured guidance from antimicrobial stewardship to consider discontinuing or de-escalating antibiotics. This guidance, which will include an explicit calculation of the post-test probability of bacterial infection based on considering risk factors, vital signs, symptoms, and available imaging, will be communicated to the primary care team via direct electronic message and a summary note in the patient's chart. The final decision on whether to continue antibiotic therapy will be up to the primary team. The primary outcome of interest will be in-hospital antibiotic use. Safety outcomes will include length of stay, readmissions, hospital-free days, and mortality..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ClinicalTrials.gov - (2024) vom: 20. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: August 4, 2023, Last downloaded: ClinicalTrials.gov processed this data on February 28, 2024, Last updated: February 28, 2024 |
|---|
| Study ID: |
NCT05976581 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG009385517 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG009385517 | ||
| 003 | DE-627 | ||
| 005 | 20240228010501.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230809s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG009385517 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT05976581 | ||
| 035 | |a (UBBS_Klinische_Studien)HP-00103497 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients |b Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: August 4, 2023, Last downloaded: ClinicalTrials.gov processed this data on February 28, 2024, Last updated: February 28, 2024 | ||
| 520 | |a Low-risk patients with viral pneumonia do not benefit from and may be harmed by antibiotic therapy. In this study, an alert will appear in the electronic health record of patients undergoing molecular diagnostic testing for respiratory symptoms that provides options for diagnostic testing based on pre-test probability of bacterial infection. Patients with test results suggesting possible viral infection will be randomized to either usual care or to receive test results along with structured guidance from antimicrobial stewardship to consider discontinuing or de-escalating antibiotics. This guidance, which will include an explicit calculation of the post-test probability of bacterial infection based on considering risk factors, vital signs, symptoms, and available imaging, will be communicated to the primary care team via direct electronic message and a summary note in the patient's chart. The final decision on whether to continue antibiotic therapy will be up to the primary team. The primary outcome of interest will be in-hospital antibiotic use. Safety outcomes will include length of stay, readmissions, hospital-free days, and mortality. | ||
| 650 | 2 | |a Pneumonia | |
| 650 | 2 | |a Pneumonia, Viral | |
| 650 | 2 | |a Pneumonia, Bacterial | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Recruiting | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 20. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:20 |g month:02 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT05976581 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 20 |c 02 | ||